DRD2 and diffuse midline glioma: In recent years, there have been an increasing number of studies on gene targeting therapy, and some of these approaches have been used in the clinic [18], Some studies have shown that ONC201, a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3), may be effective for Diffuse midline gliomas, H3K27-altered [19].